

# Responsive Governance: Shifting Ethical Paradigms and Practices for Repositories

Edwards KA<sup>1,2,4</sup>, Anderson NR<sup>1,3</sup>, Fearn PA<sup>1,3</sup>, & Fullerton SM<sup>1,2,4</sup>

<sup>1</sup>Institute of Translational Health Sciences, <sup>2</sup>Dept Bioethics & Humanities, <sup>3</sup>Dept Medical Education and Biomedical

## BACKGROUND

The challenges of large-scale translational biorepository research require a new and responsive approach to research ethics. The evolving needs of patients, researchers, and institutions are core to advancing and sustaining human subjects' regulations and research ethics practices. Researchers are:

- Challenged by new demands for data sharing and secondary use
- Often will not have met the contributing patient
- May not have identifiers or protocols that would permit re-contact

Alternative practices are needed to demonstrate respect for participants and build trust in this setting of enforced anonymity.

## EMERGING DATA

Data shows that the public is concerned about privacy but that they are still willing to donate their data to repositories.

People will make their own risk/benefit calculations and will be willing to take risks if the presumed benefit is valued, or the person who is asking is a trusted source.

Because of the wide variability in public values and preferences, having a dynamic, responsive governance mechanism will be critical to the integrity of the system.

### 2008 randomized public survey of 4659 (Kaufman et al. 2009):

- 90% were concerned about privacy protections
- 60% would participate in a biobank if asked
- 48% would provide consent for all research if approved by an oversight board, 42% wanted to be asked for each use
- 37% were worried the data could be used against them
- 92% would allow academic researchers to use data; 80% "govt researchers"; 75% industry
- Receiving research results, or \$200, made a difference in interest in participating and lessened concerns about privacy

### Telephone interviews were conducted with 1,193 patients recruited from clinics (Hull et al. 2008):

- 72% wanted to know about research being done with anonymous samples; 81% with identifiable samples
- 37% of reasons for wanting to know about what research was done were curiosity-based.
- 57% would require researchers to seek permission, whereas 43% would be satisfied with notification only.

## CONSENT

"Blanket" consent is not meaningful, and from some studies, is also misleading for participants.


Alternatives to blanket, or open, consent include:

- o Initial consent to a process for deciding how their samples will be used
- o Re-consent for prospective studies without clear consent direction
- o Re-contact for participation in new research endeavors possible
- o Re-contact when institutional or oversight review identifies new risks

We should explore new methods of re-contact (automated, electronic communication), which:

- o Potentially aids in initial recruitment
- o Donor involvement in enlisting others
- o Keeps participants engaged and informed about repository activities
- o Builds and sustains relationships, which are important to trust

for Genomics and Healthcare Equality



From first-generation to next-generation biorepository research, changes are expected in the following areas:

- (A) DNA markers to trace specific samples back to specific individuals, making anonymized samples identifiable
- (B) Identifiable human subjects make IRB review a necessity
- (C) Oversight suggests need for on-going interactions with donors
- (D) Data sharing is subject to self-regulation stewardship

As represented by the vertical arrows, next-generation research will require greater attention to

## EVOLVING MODELS OF STEWARDSHIP

### Shared coded data and on-going contact with donors requires sustained stewardship of materials

- o Accountability for research uses
- o Robust mechanisms for addressing unanticipated questions
- o Custodianship, not ownership, of research materials
- o Appropriate roles for participants in research decision-making

### Previously proposed stewardship models:

- Steward assumes responsibility for donor's intent, the manner resources are used, and the outcomes from their use (Jeffers 2001)
- Combination of formal regulatory bodies such as IRBs as research gatekeepers and government bodies that pass legislation, plus informal bodies such as professional organizations and funders working in

## MODELS OF PARTICIPATORY GOVERNANCE

- **Public Engagement**
  - o BC Bioblibrary, Mayo (O'Doherty, Burgess, Koenig)
  - o Public engagements informed policy
- **Participant Advisory Boards**
  - o NW Kidney Research Center, SPORE Consortium
  - o Equal standing with Scientific Board
- **Donor's Association**
  - o Charitable trust model (Winickoff)
  - o Democratic identification of common interests
- **Participant Owned and Governed**
  - o AGRE, PXE International (Terry)
  - o High degree of control and accountability

## ACCOUNTABILITY

A research repository governance system will need to build in accountability mechanisms that:

- Track the research uses of repository samples and data (audit trails)
- Develop plans for risk management
- Establish recourse or consequences if breaches occur

Accountability mechanisms may need to evolve at the local (repository-specific), institutional, and national (funding) levels

Transparency about the systems for accountability will help enhance trust

- Effective communication strategy
- Audit trails through informatics solutions

## RETURN OF RESULTS

Changing participant expectations suggest repository managers will need to anticipate, and develop systems to support, the routine return of results

- On-going governance to decide which results should be returned, and when
- Identifying effective means of communication

Research is needed to determine if participants interests will be best met by the return of individual or aggregate findings

- Some incidental findings will need to be returned
- Novel bioinformatic approaches may simplify

Open-ended nature of research means that extra effort to maintain contact details will be needed

## SELECTED CITATIONS

- Burgess M et al. Biobanking in BC: Enhancing discussions of the future of personalized medicine through deliberative public engagement. *Pers Med* 2008;5(3): 285-296.
- Fullerton, SM et al. Meeting the governance challenges of next generation biorepository research. *Science Trans Med* 2010; 2, 15cm3.
- Fryer-Edwards K, Fullerton SM. Relationships with test-tubes: where's the reciprocity? *Am J Bioeth.* 2006;6(6):36.
- Greely HT. Uneasy ethical and legal underpinnings of large-scale genomic biobanks. *Annu Rev Genomics Hum Genet* 2007; 8, 343-64.
- Hull SC et al. Patients' views on identifiability of samples and informed consent for genetic research. *Am J Bioeth.* 2008 Oct;8(10):62-70.
- Kaufman DJ et al. Public opinion about the importance of privacy in biobank research. *Am J Hum Genet.* 2009 Nov;85(5):643-54.
- Mascalzoni D et al. with EUROSPAN consortium. Comparison of participant information and informed consent forms of five European studies in genetic isolated populations. *Eur J Hum Genet.* 2010 Mar;18(3):296-302.
- Ohm P. Broken Promises of Privacy: Responding to the Surprising Failure of Anonymization. *UC Law Legal Studies Research Paper.* 2009 August 13;09-12.
- Patel AA et al. An informatics model for tissue banks--lessons learned from the Cooperative Prostate Cancer Tissue Resource. *BMC Cancer* 2006; 6, 120.
- Tutton R et al. Governing UK Biobank: the importance of ensuring public trust. *Trends Biotechnol.* 2004 Jun;22(6):284-5.
- Williams G, Schroeder D. Human genetic banking: altruism, benefit and consent. *New Genet Soc* 23, 89-103 (2004).
- Yarborough M et al. Transforming the Culture of Biomedical Research from Compliance to Trustworthiness. *Academic Medicine.* 2009 Apr;84(4):472-7.

## ACKNOWLEDGEMENTS

This research was made possible in part by funding through NHGRI Grant P50 HG003374 (Burke, PI), University of Washington, Center for Genomics and Healthcare Equality; NCCR Grant UL1 RR025014 (Disis, PI), University of Washington, Institute of Translational Health Sciences and NLM training grant (NIH NLM #T15 LM07442).